Overview
The customer is a global biopharmaceutical company developing innovative medicines in thefields of proprietary commercial products focused on addiction and schizophrenia, along witha pipeline of product candidates in development for schizophrenia, bipolar disorder,neurodegenerative disorders and cancer.
Challenges
- Difficulty in analysing input of different database structures from paper CRF, eCRF, inhouse and outsourced data management, and local investigator files
- Existing standard programs were only study/client specific and lacked key variables for broader use
- Non-availability of Macros for derived responses and efficacy endpoints on RECIST criteria
- Creation of Kaplan Meier graphs for end points was going through a lot of manual programming
- Study Integration efforts were experiencing untimely hick-ups because of no standards across studies
Outcomes
Maximized the functionalities of end output production to have submission ready outputs like Kaplan Meier graphs for PFS, OS, ORR, DOR endpoints
Drastic reduction in timeline to derive all the information needed in terms of content and layout
Creation of a standard norm in terms of handling RECIST data that improved the efficiency and consistency across all projects
Considerable reduction in programming resources used for manual programming